Agnos leverages an alllogeneic cell therapy using human iPSC-derived photoreceptor precursors to restore photoreceptor function across a broad range of loss-of-function IRDs.
INDICATIONSMid-stage autosomal recessive rod-cone dystrophies
MODALITYCell Therapy
STAGEEarly preclinical
PUBLIC/PRIVATEPrivate
FUNDDiscovery Fund
Amber Bio is pioneering new RNA editing modalities to treat previously undruggable patient populations.
INDICATIONSUndisclosed
MODALITYMulti-kb RNA-editing platform
STAGEDiscovery/Preclinical
FUNDCore Fund
Atsena Therapeutics is developing novel AAV-based gene therapies for monogenic inherited retinal diseases.
INDICATIONS LCA1, XLRS, USH1B, STGD
MODALITYNovel AAV-based gene therapy
STAGEClinical
Beacon Therapeutics is developing genetic therapies for the treatment of rare and prevalent ocular diseases.
INDICATIONS XLRP, Dry AMD
MODALITYAAV-based Gene Therapy
PRIVATE/PUBLICPrivate
Nacuity is developing targeted therapies aimed at preventing oxidative tissue damage, a driver of blinding eye disease.
INDICATIONS RP, Nephropathic Cystinosis
MODALITYOral small molecule anti-oxidant
NVasc is an early-stage ophthalmology company focused on treating the dry AMD spectrum through choroidal and retinal revascularization.
INDICATIONS Dry AMD/GA
MODALITYLIFR-agonist for revascularization
Opus is a mission based AAV gene therapy company created for treatment of inherited retinal diseases
INDICATIONS LCA5, BEST1, RDH12, MERTK
MODALITYAAV-based gene therapy
PRIVATE/PUBLICPublic
Perceive Bio aims to target risk alleles for dry AMD and GA, target regulation of the complement system, and key retinal neuroprotective pathways.
INDICATIONS Dry AMD/GA, Neuroprotection
Perceive Pharma is pioneering novel small molecule neuroprotective therapeutics, with lead pipeline programs in glaucoma and other ophthalmic diseases
INDICATIONSGlaucoma, Undisclosed
MODALITYSmall molecule neuroprotection
STAGEPreclinical
Salution Health combines clinical and regulatory strategy consulting with proprietary agentic AI to accelerate therapeutic development .
INDICATIONSAll ophthalmology
MODALITYAI-powered regulatory and clinical consultancy
STAGEGo to Market
SparingVision is a genomic medicine company developing mutation independent and dependent therapies designed to prevent retinal degeneration.
INDICATIONS Mid and Late stage mutation independent RP
MODALITYnovel AAV gene therapy delivery
CheckedUp is a physician-founded, physician-run patient education company offering tech-enabled patient engagement solutions.
INDICATIONS Healthcare Technology Platform
Acquired by Rockbridge
Nayan was developing mutation agnostic therapies for IRD’s that preserve cone function by downregulation of rod-specific genes.
INDICATIONS Mutation Independent IRD’s
MODALITYSmall-molecule
Dissolved
ProQR is developing unique RNA therapies for severe rare and common diseases.
INDICATIONS CEP290, USH2A
MODALITYASO (RNA) platform
Ophthalmic asset divestiture
SalioGen is developing a novel mammallian-derived enzyme, saliogase, for editing, replacing or augmenting DNA without double-strand breaks or relying on host repair or homologous recombination.
INDICATIONS STGD
MODALITYSalioGase editing platform
STAGEDiscovery
Stargazer was developing a visual cycle modulator aimed at reducing pathologic accumulation of cytotoxic retinoids in the retina.
INDICATIONS STGD, Dry AMD
MODALITYSmall Molecule
Solvent Dissolution
Vedere Bio I leveraged a mutation agnostic optogenetic technology with the aim of restoring vision due to photoreceptor cell death.
INDICATIONS Late-Stage RP (mutation independent)
MODALITYOptogenetic Platform
Acquired by Novartis
Vedere Bio II
INDICATIONSLate-Stage RP (mutation independent)
